Contact Us
Peptides and Oligonucleotide API Development and Manufacturing
Discover how CPC Scientific’s decades of experience in GMP manufacturing can support your peptide and oligonucleotide needs throughout the therapeutic lifecycle with our comprehensive CRDMO services. We specialize in synthetic peptide and oligonucleotide manufacturing for early-, late-phase development, and commercial production. CPC Scientific has had over 100 projects in clinical development (phases 1,2 and 3) with 10 commercial projects.
We are delighted to inform our clients that starting in 2024, CPC Scinetific will offer US-based manufacturing for peptide APIs. Building resilient supply chains will protect the United States from experiencing shortages of critical therapeutic products. CPC Scientific’s Rocklin, CA manufacturing facility will address the critical supply chain needs for peptide API’s beginning in 2024.
We would be happy to provide you with a peptide, oligonucletoide, or conjugate (POC) quotation:
GMP PROJECTS BY REGION
Global Late-Phase and Commercial Experience
| Project Location | Development Stage | |
|---|---|---|
 | USA | Approved |
 | Japan | Approved |
 | Europe Union | Approved |
 | UK | Approved |
 | Switzerland | Approved |
 | China | Approved |
 | Australia | Approved |
 | Russia and CIS | Approved |
Contact Us
Connect with the right peptide expert now. CPC Scientific offers solutions in custom peptide synthesis, GMP manufacturing, late-phase drug development, and commercial manufacturing. Let us know your challenge and we’ll get back to you within 24 hours.
Latest Briefing from our Knowledge Center
Press Releases, Industry News, Events, and Technical Content
Join us as we celebrate a proud milestone: the successful listing of Medtide Inc., parent company of CPC Scientific, on the main board of the Hong Kong Stock Exchange in June 2025. This moment marks a new chapter of growth, innovation, and global impact for our organization.
We are excited to share that CPC Scientific Inc. has officially received the Good Manufacturing Practice (GMP) Certificate in accordance with the ISO 22716:2007(E) Cosmetic Guidelines.
This […]
Nakagawa, Mayumi, Teresa Evans, Milan Bimali, Hannah Coleman, Jasmine Crane, Nadia Darwish, Jennifer L. Faulkner et al. MedRxiv (2025): 2025-01.
Singh, S.S., Calvo, R., Kumari, A., Sable, R.V., Fang, Y., Tao, D., Hu, X., Castle, S.G., Nahar, S., Li, D. and Major, E. Molecular Cancer Therapeutics (2024).
Alvarez, N., Adam, G.C., Howe, J.A., Sharma, V., Zimmerman, M.D., Dolgov, E., Rasheed, R., Nizar, F., Sahay, K., Nelson, A.M. and Park, S. Viruses 16, no. 7 (2024): 1158.
Liu, J., Heddleston, J., Perkins, D.R., Chen, J.J.H., Ghanbarpour, A., Smith, B.W., Miles, R., Aihara, E. and Afshar, S. Scientific Reports 14, no. 1 (2024): 13437.
CPC announces the completion of a rigorous four-day audit conducted by Australia’s Therapeutic Goods Administration (TGA), the country’s government authority responsible for evaluating, assessing, and monitoring approved products defined as therapeutic goods.
Alencar-Silva, Thuany, Stefhani Martins de Barcelos, Amandda Silva-Carvalho, Mauricio Gonçalves da Costa Sousa, Taia Maria Berto Rezende, Robert Pogue, Felipe Saldanha-Araújo et al. Cells 13, no. 10 (2024): 813.